Trial Profile
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms Alliance
- 03 Aug 2022 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results of an exploratory analysis assessing Deficit accumulation frailty index scores and exploring their relationship with treatment outcomes for older AML patients using data from two clinical studies: Alliance/CALGB 11001 and Alliance/CALGB 11002 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology